Last reviewed · How we verify

Dermira, Inc. — Portfolio Competitive Intelligence Brief

Dermira, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Olumacostat Glasaretil Gel, 5.0% Olumacostat Glasaretil Gel, 5.0% phase 3 SOAT1 inhibitor SOAT1 (sterol O-acyltransferase 1) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Agomab Spain S.L. · 1 shared drug class
  2. Avalo Therapeutics, Inc. · 1 shared drug class
  3. Bristol-Myers Squibb · 1 shared drug class
  4. Celltrion · 1 shared drug class
  5. Centocor, Inc. · 1 shared drug class
  6. Clinique des Céphalées de Montréal · 1 shared drug class
  7. European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class
  8. Gliknik Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dermira, Inc.:

Cite this brief

Drug Landscape (2026). Dermira, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dermira-inc. Accessed 2026-05-16.

Related